Document review
Illume Research may request institutional, professional, laboratory, end-use, import, or destination evidence before proceeding.
Regulatory information · Version 2026-07
A research-only label is not a universal legal exemption.
General information, not legal advice
This page does not determine product classification, licensing, legality, or destination eligibility. Illume Research must obtain jurisdiction-specific professional advice before accepting live orders.
Regulatory posture
No approval or endorsement claim
Illume Research does not state or imply that the organisation, website, catalogue, or any product is approved, authorised, licensed, registered, certified, endorsed, or inspected by the FDA, DEA, EMA, MHRA, or any other authority unless documentary evidence and qualified legal review support that exact claim.
The FDA's published RUO guidance addresses when certain in vitro diagnostic products are properly labelled for research or investigational use. Illume Research does not treat that guidance as a blanket exemption for the compounds listed here.[1]
The MHRA states that it regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. A research-only presentation therefore must not be used to imply that UK regulatory requirements are irrelevant.[2]
Authority matrix
Authorities potentially relevant to supply
Relevance depends on product classification, destination, proposed activity, claims, intended use, and applicable law. This matrix is not exhaustive.
| Region | Potential authorities | Website posture |
|---|---|---|
| United States | FDA; DEA where controlled-substance rules apply; federal and state authorities | Classification, intended use, claims, import, distribution, and possession must be assessed for each product and activity. |
| European Union / EEA | EMA and relevant national competent authorities | EU-level and national requirements may differ by product classification, destination, research setting, and activity. |
| United Kingdom | MHRA and other relevant UK authorities | The site does not state or imply MHRA approval, licensing, registration, or an exemption from medicines law. |
| Other destinations | National medicines, chemicals, customs, import/export, sanctions, workplace-safety, and research authorities | Illume Research may restrict or decline any destination until appropriate review is complete. |
End-user responsibilities
01
Confirm lawful acquisition, possession, import, export, transport, storage, handling, use, recordkeeping, and disposal in every relevant jurisdiction.
02
Maintain suitable facilities, trained personnel, risk assessments, safety procedures, and any institutional approvals required for the proposed work.
03
Provide accurate institutional, researcher, destination, and intended-purpose information and promptly disclose any material change.
04
Use materials only for the accepted controlled, non-clinical research purpose and prevent diversion, unauthorised access, relabelling, resale, or onward supply.
05
Review the batch-specific COA and other available documentation before use; do not treat a pending, generic, or third-party document as a regulatory approval.
Prohibited uses
01
Human or veterinary consumption, administration, treatment, diagnosis, prevention, enhancement, supplementation, or other clinical use.
02
Use in food, drink, cosmetics, household products, consumer goods, or any product intended for personal use.
03
Dosing advice, administration instructions, therapeutic claims, performance claims, or marketing that suggests suitability for human or veterinary use.
04
Resale, relabelling, repackaging, compounding, manufacturing, or onward supply without prior written acceptance and all required legal authorisations.
05
Any unlawful, deceptive, unsafe, sanctioned, restricted, or diversionary activity.
Destination controls
Locations, institutions, individuals, and products may be restricted or declined based on legal, sanctions, safety, policy, or operational review.
Independent legal review
Before launch, qualified counsel should review product classification, licences, advertising, trade controls, privacy, tax, and consumer-law implications.
Continue to the purchase terms
Submission is a request for review—not an accepted order, stock reservation, or payment transaction.
References
- [1] U.S. Food and Drug Administration, Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only.
- [2] UK Government, Medicines and Healthcare products Regulatory Agency.